Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ACLX Arcellx Inc
- Stocks
- Healthcare
- NASDAQ: ACLX
Price (delayed)
$58.25
Market cap
$3.21B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.99
Enterprise value
$3.18B
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which
Highlights
Arcellx's debt has decreased by 39% YoY
Arcellx's quick ratio has decreased by 9% YoY but it has increased by 3% from the previous quarter
The EPS has dropped by 190% year-on-year and by 50% since the previous quarter
Arcellx's net income has plunged by 51% from the previous quarter
Key stats
What are the main financial stats of ACLX
Market
Valuations
Earnings
Shares outstanding
55.11M
Market cap
$3.21B
Enterprise value
$3.18B
Price to earnings (P/E)
N/A
Price to book (P/B)
7.68
Price to sales (P/S)
41.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
41.43
Revenue
$76.81M
Gross profit
$76.81M
Operating income
-$190.66M
Net income
-$162.42M
EBIT
-$193.22M
EBITDA
-$186.73M
Free cash flow
-$122.49M
Per share
Balance sheet
Liquidity
EPS
-$2.99
EPS diluted
-$2.99
Free cash flow per share
-$2.22
Book value per share
$7.59
Revenue per share
$1.39
TBVPS
$11.73
Total assets
$648.08M
Total liabilities
$231.18M
Debt
$53.19M
Equity
$416.91M
Working capital
$441.69M
Debt to equity
0.13
Current ratio
4.93
Quick ratio
4.83
Net debt/EBITDA
0.15
Margins
Efficiency
Dividend
EBITDA margin
-243.1%
Gross margin
100%
Net margin
-211.5%
Operating margin
-248.2%
Return on assets
-22.7%
Return on equity
-35.3%
Return on invested capital
-35.2%
Return on capital employed
-36.1%
Return on sales
-251.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACLX stock price
How has the Arcellx stock price performed over time
Intraday
-2.1%
1 week
10.32%
1 month
-1.52%
1 year
17.04%
YTD
-24.04%
QTD
-11.2%
Financial performance
How have Arcellx's revenue and profit performed over time
Revenue
$76.81M
Gross profit
$76.81M
Operating income
-$190.66M
Net income
-$162.42M
Gross margin
100%
Net margin
-211.5%
The company's operating income has shrunk by 153% YoY and by 39% QoQ
Arcellx's net margin has plunged by 113% from the previous quarter
Arcellx's operating margin has plunged by 95% from the previous quarter
Arcellx's net income has plunged by 51% from the previous quarter
Price vs fundamentals
How does ACLX's price correlate with its fundamentals
Growth
What is Arcellx's growth rate over time
Valuation
What is Arcellx stock price valuation
P/E
N/A
P/B
7.68
P/S
41.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
41.43
The EPS has dropped by 190% year-on-year and by 50% since the previous quarter
The equity has declined by 16% year-on-year and by 8% since the previous quarter
ACLX's price to book (P/B) is 7% lower than its last 4 quarters average of 8.3
The company's revenue fell by 42% YoY and by 29% QoQ
The price to sales (P/S) is 25% higher than the last 4 quarters average of 33.6
Efficiency
How efficient is Arcellx business performance
The company's return on equity has shrunk by 169% YoY and by 58% QoQ
ACLX's return on invested capital has dropped by 111% year-on-year and by 47% since the previous quarter
The return on sales has dropped by 97% since the previous quarter
Arcellx's return on assets has shrunk by 58% QoQ
Dividends
What is ACLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACLX.
Financial health
How did Arcellx financials performed over time
ACLX's total assets is 180% higher than its total liabilities
Arcellx's total liabilities has decreased by 18% YoY and by 10% from the previous quarter
ACLX's total assets is down by 17% YoY and by 9% QoQ
Arcellx's debt is 87% less than its equity
Arcellx's debt has decreased by 39% YoY
ACLX's debt to equity is down by 28% year-on-year but it is up by 8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.